In last trading session, Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) saw 0.48 million shares changing hands with its beta currently measuring 1.52. Company’s recent per share price level of $10.80 trading at $0.08 or 0.75% at ring of the bell on the day assigns it a market valuation of $965.52M. That closing price of AVDL’s stock is at a discount of -56.02% from its 52-week high price of $16.85 and is indicating a premium of 45.19% from its 52-week low price of $5.92. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.85 million shares which gives us an average trading volume of 551.72K if we extend that period to 3-months.
For Avadel Pharmaceuticals plc ADR (AVDL), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.31 in the current quarter.
Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) trade information
Upright in the green during last session for gaining 0.75%, in the last five days AVDL remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $10.80 price level, adding 6.66% to its value on the day. Avadel Pharmaceuticals plc ADR’s shares saw a change of 50.84% in year-to-date performance and have moved 1.31% in past 5-day. Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL) showed a performance of 5.16% in past 30-days. Number of shares sold short was 4.0 million shares which calculate 7.29 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $20.00 to the stock, which implies a rise of 46.0% to its current value. Analysts have been projecting $17.00 as a low price target for the stock while placing it at a high target of $26.00. It follows that stock’s current price would drop -140.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of -57.41% for stock’s current value.
Avadel Pharmaceuticals plc ADR (AVDL) estimates and forecasts
Statistics highlight that Avadel Pharmaceuticals plc ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -24.26% of value to its shares in past 6 months, showing an annual growth rate of 13.54% while that of industry is 10.50. Apart from that, the company came raising its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 32.60% in the current quarter and calculating 43.70% increase in the next quarter.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $15.84 million for the same. And 6 analysts are in estimates of company making revenue of $20.56 million in the next quarter that will end on Mar 2024.
In 2023, company’s earnings growth rate is likely to be around 14.52% while estimates for its earnings growth in next 5 years are of 15.00%.
Avadel Pharmaceuticals plc ADR is more likely to be releasing its next quarterly report on November 08 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Avadel Pharmaceuticals plc ADR (NASDAQ:AVDL)’s Major holders
Insiders are in possession of 4.98% of company’s total shares while institution are holding 63.74 percent of that, with stock having share float percentage of 67.08%. Investors also watch the number of corporate investors in a company very closely, which is 63.74% institutions for Avadel Pharmaceuticals plc ADR that are currently holding shares of the company. Janus Henderson Group PLC is the top institutional holder at AVDL for having 7.52 million shares of worth $123.97 million. And as of Jun 29, 2023, it was holding 8.42% of the company’s outstanding shares.
The second largest institutional holder is RTW Investments LP, which was holding about 6.81 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 7.62% of outstanding shares, having a total worth of $112.24 million.
On the other hand, Janus Henderson Global Life Sciences Fund and Janus Henderson Venture Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 1.78 million shares of worth $29.42 million or 2.00% of the total outstanding shares. The later fund manager was in possession of 0.28 million shares on Jun 29, 2023, making its stake of worth around $4.64 million in the company or a holder of 0.31% of company’s stock.